Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Go back to Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 33.68 -1.19 (3.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.87 | 52 Week High | $5.17 | |||
| Open | $34.63 | 52 Week Low | $0.94 | |||
| Day High | $34.81 | P/E | N/A | |||
| Day Low | $33.53 | EPS | $0.00 | |||
| Volume | 1,867,689 | |||||
